Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences Psychedelics Investing
Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway Psychedelics Investing
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board Psychedelics Investing
Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights Psychedelics Investing
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs Psychedelics Investing
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference Psychedelics Investing
